You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma

Article metrics

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma

 

Online download statistics by month:

Online download statistics by month: February 2020 to June 2025

AbstractFullPdf
Feb 2020586586327
Mar 2020395395223
Apr 2020278278118
May 202028228249
Jun 202021021068
Jul 202019719768
Aug 202011010851
Sep 202013713748
Oct 202013813869
Nov 202017417360
Dec 202013813850
Jan 2021166166104
Feb 202115515552
Mar 202117517552
Apr 202116616657
May 202111011142
Jun 202111711747
Jul 202112512535
Aug 202112412459
Sep 202113013044
Oct 202115515572
Nov 202112612558
Dec 202110010035
Jan 202210911639
Feb 2022737532
Mar 2022889235
Apr 2022828537
May 202212612736
Jun 2022899234
Jul 2022949627
Aug 202211211428
Sep 202213914261
Oct 202216716926
Nov 202211111433
Dec 202211911919
Jan 202312813031
Feb 202313313325
Mar 202310310425
Apr 2023989825
May 202310510627
Jun 2023656714
Jul 2023848435
Aug 2023757520
Sep 2023585827
Oct 202314914921
Nov 202324824822
Dec 2023848530
Jan 2024444531
Feb 2024656525
Mar 202410110293
Apr 2024979847
May 2024838540
Jun 2024818231
Jul 2024899032
Aug 2024646422
Sep 2024616222
Oct 2024606144
Nov 2024858639
Dec 2024889026
Jan 2025656525
Feb 202510410632
Mar 2025535324
Apr 2025919224
May 2025676739
Jun 2025484922
Total827983313115